Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PGEN
PGEN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PGEN News
Precigen Announces PAPZIMEOS as New Standard of Care for RRP Treatment
Jan 20 2026
PRnewswire
Precigen Receives FDA Approval for PAPZIMEOS, Surpassing 200 Patient Registrations
Jan 12 2026
Newsfilter
Precigen CEO Helen Sabzevari to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 05 2026
PRnewswire
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
Dec 29 2025
Benzinga
DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion
Dec 29 2025
Benzinga
Promega Collaborates with Oxford to Accelerate Precision Medicine Research
Dec 09 2025
Businesswire
HC Wainwright & Co. Reaffirms Buy Rating for Precigen (PGEN)
Nov 15 2025
NASDAQ.COM
Purchase Precigen at $3.50 and Achieve 27.1% Returns Through Options
Nov 14 2025
NASDAQ.COM
Biotech Stocks Rise for Vaxart and Precigen Following Q3 Earnings Reports
Nov 14 2025
SeekingAlpha
Earnings Report for November 13, 2025: After-Hours Updates on AMAT, BAP, STN, GLOB, TMC, TRVI, PGEN, BZH, OMER, TBN, TOI, AIRJ
Nov 13 2025
NASDAQ.COM
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Nov 13 2025
PRnewswire
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Nov 06 2025
PRnewswire
Patient Capital Makes Significant Investment in Precigen (PGEN) with Purchase of 10.2 Million Shares
Nov 01 2025
NASDAQ.COM
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Oct 13 2025
PRnewswire
Two Healthcare Stocks Have Recently More Than Doubled and May Rise Even Further, Say Wall Street Analysts
Sep 07 2025
NASDAQ.COM
Precigen Obtains $125 Million Credit Facility from Pharmakon to Propel PAPZIMEOS Commercialization
Sep 03 2025
NASDAQ.COM
Show More News
